GSK3B and Alzheimer disease: Decreased tau hyperphosphorylation observed with certain GSK-3β inhibitors suggests p-tau inhibition which is probably a common way of alleviating AD (Paquet et al., 2009; Nery et al., 2014; Zanandrea et al., 2018; Koehler et al., 2019).